Richard R. Furman, M.D., discusses second-generation BTK inhibitors, such as acalabrutinib and BGB-3111 in chronic lymphocytic leukemia (CLL). Read more
Clinical trials in patients with follicular lymphoma (FL) mandate that patients undergo bone marrow biopsies (BMBs) at baseline and at subsequent points following treatment in order to monitor response, but the biopsies are unnecessary in most patients, argues Sarah Rutherford, M.D., and colleagues. Read more
Four interdisciplinary teams of physicians and scientists from Weill Cornell Medicine have been announced as recipients of the Sandra and Edward Meyer Cancer Center's inaugural Collaborative Research Initiative pilot project grants. Read more
Bishoy Faltas, M.D., has been awarded a Career Development Award from the Department of Defense to investigate the biology of a family of proteins thought to drive resistance to chemotherapy in the advanced stages of bladder cancer. Read more
Genetic mutations caused by rearranged chromosomes drive the development and growth of certain colorectal cancers, according to new research conducted by Weill Cornell Medicine investigators. Many of the genetic mutations... Read more
Genetic mutations caused by rearranged chromosomes drive the development and growth of certain colorectal cancers, according to new research conducted by Lukas Dow, Ph.D. Read more
An enzyme implicated in autoimmune diseases and viral infections also regulates radiation therapy’s ability to trigger an immune response against cancer, according to Sandra Demaria and colleagues. Read more
Adult T-cell lymphoma/leukemia (ATLL), a rare subtype of peripheral T-cell lymphoma, presents very differently and can be more prevalent in certain worldwide demographics compared with others, explains Adrienne A. Phillips, M.D. Read more